报价延迟最少15分钟:2025/07/21 07:04 EDT
盘前时段
|
||||
|
1.59 
|
|
|
常规时段
|
|
|
|
|
||||||||||||
|
|
|
|
|
1.585
|
|
|
| 价值评估 |
|
盈利(现时/预测)
-0.83/-0.77
|
|
企业价值
48.59M
|
| 资产负债 |
|
每股账面净值
0.19
|
| 现金流量 |
|
现金流量率
--
|
| 损益表 |
|
收益
0
|
|
每股收益
0.00
|
|
同行比较
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
报价延迟最少15分钟：2025/07/21 07:04 EDT
同行比较之报价最少15分钟延迟
|
业务概览
|
|||
| Gain Therapeutics Inc is a biotechnology company developing novel small molecule therapeutics to treat diseases across several therapeutic areas, including, lysosomal storage disorders, central nervous system disorders, metabolic disorders, and oncology. The company's clinical-stage product candidate, GT-02287, is being developed for the treatment of GBA1 Parkinson's disease. The company uses its computational target and drug discovery platform, Magellan, to discover novel allosteric binding sites on proteins implicated in disease and to identify proprietary small molecules that bind these sites to modulate protein function and treat the underlying cause of the disease. Geographically, the company operates inSwitzerland, Spain, the United States, and Australia. |
